Puyuan Bio

About:

Puyuan Bio engages in the clinical quantitative detection of tumor-specific mRNA in human peripheral blood.

Top Investors: West Lake Science and Technology Direct Investment Fund, Xinghua Dingli, Shanghai Jiaotong University Source Fund

Description:

Puyuan Bio engages in the clinical quantitative detection of tumor-specific mRNA in human peripheral blood. Its technology can provide an important clinical diagnosis basis for the presence of hematogenous spread of tumor cells and dynamic monitoring of the disease. The company has a talented team with doctoral tutors, doctors, and masters as the main body, and has 9 national invention patents in related fields. The company was approved by the Ministry of Science and Technology of Science and Technology Small and Medium Enterprises Technology Innovation Fund and passed the acceptance inspection. It is an enterprise settled in the technology transfer plan of Anhui Province and has been included in the Hefei Shuangqian Project. It was supported by the Development and Reform Commission in 2018. The registration application materials of the cytokeratin 19 (CK19) mRNA nucleic acid detection kit (PCR-fluorescent probe method) have been accepted by the State Food and Drug Administration, the on-site inspection of the medical device production quality management standard has been passed, and the approval number will be obtained soon. When it is put into production, it will contribute to public health.